Financial Shenanigans

The Forensic Verdict

Yatsen's reported numbers are broadly a faithful representation of a money-losing turnaround, not a polished façade. The biggest forensic data points are concentrated on the capital-allocation and acquisition side (a ¥714M cumulative goodwill writedown from the 2020–21 Eve Lom / Galénic / DR.WU deals, ¥1.38B of buybacks funded from IPO cash while operating cash flow stayed negative for five of six years), not on the revenue line. There is no restatement, no auditor resignation, no going-concern flag, and the only material securities-fraud class action was dismissed by the SDNY on July 22, 2024. The single data point that would most change the grade is the FY2026 20-F's first audit under the new audit-committee chair, given the independent-director rotation on February 28, 2026.

The 3-year CFO-to-net-income ratio of 29% and FCF-to-net-income ratio of 38% are both below 1.0x, but both numerator and denominator are negative — meaning cash burn has been smaller than the reported GAAP loss because the losses are heavy with non-cash items (share-based compensation in FY20–21, intangible amortization on acquired brands, ¥714M of cumulative goodwill impairment in FY22–FY24). That is the opposite direction of typical earnings-quality shenanigans, where cash trails earnings. Here, reported earnings have been more pessimistic than cash, and the gap is narrowing because the impairment cycle has finished.

Shenanigans Scorecard

The map concentrates exclusively in the yellow band. There are no red flags but seven yellow ones, and they cluster in two themes: acquisition residue (A3, A7, B3, C1) and governance / metric framing (C2 and breeding ground). The income-statement / revenue-recognition family (A1, A2, A4, A6, B1, B2) is clean.

Breeding Ground

Yatsen's governance setup leans toward founder control with limited independent challenge, but the structure has not generated a confirmed accounting failure. The 2022 IPO-era class action (alleging misleading Perfect Diary trend disclosure) was dismissed with prejudice on July 22, 2024 by the U.S. District Court for the Southern District of New York. That dismissal is the single biggest piece of clean negative evidence.

The single highest-leverage factor here is the founder 90.7% voting control with a same-person Chairman/CEO. That structure means the audit committee, not the board majority, is the practical check on management. The chair seat changed hands ten weeks before the FY2025 20-F was filed (Sidney Xuande Huang resigned 2026-02-28; Bonnie Yi Zhang installed). Yi Zhang is a former Sina CFO and current Hesai / Swire Pacific director — substantive credentials — but a chair handover this close to a 20-F filing is a routine yellow flag for IR diligence in the next quarterly cycle.

Earnings Quality

Reported losses look real, not engineered. The income statement carries large non-cash burdens (SBC, acquired-intangible amortization, goodwill impairment) that mean GAAP earnings have been worse than underlying cash burn, the inverse of typical earnings-quality concerns. The exception is FY2025, where the GAAP loss collapsed to ¥92M and Q4 net income turned positive (¥8.1M) on an operating loss of ¥12.7M, meaning non-operating items closed the final gap.

The FY2020 ¥2.69B net loss is dominated by ¥1.9B of share-based compensation booked at IPO (founder/employee grants vested at the listing event). Post-IPO, the loss profile narrows almost linearly to FY2025's near-zero number. The operating-income line is a cleaner gauge of underlying improvement — operating margin moved from −51% (FY20) to −4% (FY25), with the bulk of the improvement coming from gross-margin expansion (64% → 78%) on skincare mix shift and SG&A normalization (114% → 79% of revenue).

Revenue vs receivables — clean

Receivables growth has lagged revenue growth in every period except FY2024. In FY2025, revenue grew 27% while receivables grew 3% and DSO compressed to 19 days. This is the clean direction — Yatsen's DTC channel mix (Tmall, JD, Douyin, RED) settles via platform reserves within days, so high DSO would be the anomaly. No evidence of channel-stuffing, bill-and-hold, or aggressive timing.

Inventory and gross-margin coherence

Gross margin and inventory days are both rising. Margin expansion is the bull case (premium skincare mix) but the persistent 170+ days of inventory is a yellow flag — if FY2026 sell-through disappoints, a write-down would land in the income statement that has just clawed back toward break-even. Inventory grew 32% in FY2025, faster than the 27% revenue growth; not a screaming red flag in a year of mix change, but it is the single most monitorable balance-sheet item for the next 20-F.

Acquisition residue — goodwill impairment trail

The goodwill / intangibles bars track the FY2020–21 acquisition wave (Eve Lom in 2020 from Manzanita Capital; Galénic and DR.WU in 2021), then ¥714M of cumulative impairment across FY2022–FY2024 brings the goodwill back to ¥155M. Translation: of roughly ¥1.13B in cash deployed for acquisitions, nearly two-thirds of the goodwill premium was subsequently written off. This is a capital-allocation and M&A-due-diligence issue more than an accounting-distortion issue — the impairments were properly recognized as they occurred — but it is the cleanest evidence that the IPO cash deployment underperformed underwriting.

Cash Flow Quality

Yatsen's operating cash flow has been negative in five of the last six years; the company has not built a CFO cushion against its losses. There is no flattering working-capital lifeline, no receivable factoring, no supplier-finance, and no investing-line reclassification masking operating costs. The cash sustaining the business is the unused IPO proceeds (¥6.7B raised in FY2020), drawn down through losses and ¥1.38B of buybacks.

The CFO line has tracked closer to zero than the net-income line in every year except FY2022, where CFO briefly turned positive on a revenue-decline-driven working-capital release. FY2022's positive CFO is mechanical, not operational — receivables and inventory shrank as revenue collapsed, freeing ¥0.4B of working capital, which the company simultaneously deployed in ¥0.65B of buybacks.

This is the picture: free cash flow has been negative or barely positive for seven consecutive years, while buybacks totaled ¥1.38B across FY22–FY25 funded by drawing down IPO cash. Buybacks while burning cash is a capital-allocation choice rather than an accounting shenanigan, but it is the single largest reason the cash pile fell from ¥5.7B (FY20) to ¥1.0B (FY25).

Investing cash flow flipped positive in FY2024 (+¥592M) and FY2025 (+¥247M) — but this is drawdown of short-term investments, transparently classified as investing inflow, not a CFO inflation tactic. The convertible-note + warrant private placement announced 2026-03-11 is the explicit acknowledgment that organic cash generation is not yet sufficient to fund operations.

Metric Hygiene

Yatsen's non-GAAP framework is conventional in its construction but routinely flatters performance during the impairment cycle. The reconciliation has been consistent — same six exclusions each year — which is the disciplined side of the practice. The problem is that "non-recurring" exclusions recurred for three consecutive years.

The headline finding: the FY24 non-GAAP profit (¥10M) sits on top of a GAAP loss of ¥708M, with ¥403M of "excluded" goodwill impairment doing most of the work. That impairment is conceptually a write-down of past M&A judgment, not a normal operating cost, but it is also the third consecutive year of "one-time" exclusions, and Beneish-style discipline says recurring items must be respected. FY25 narrows the gap to ¥89M because there was no goodwill charge — the cleanest year in the non-GAAP framework so far.

What to Underwrite Next

The forensic posture on YSG is Watch with a turnaround-trajectory caveat: there is no thesis-breaking accounting risk, but five live diligence items need quarterly tracking.

Downgrade triggers (what would push the grade to Elevated or High):

1. Any new restatement, material-weakness disclosure, or auditor change in the FY2026 20-F.
2. A fresh round of goodwill or intangible impairment in FY2026 — three impairment years would have been a pattern; a fourth would be a doctrine.
3. Inventory days above 200 for two consecutive quarters with flat or declining revenue.
4. A drop in cash + short-term investments below ¥500M without offsetting external financing.
5. A related-party transaction (loan, asset sale, brand transfer) involving the founder, Hillhouse, or ZhenFund that lacks an independent fairness process.

Upgrade triggers (what would push the grade to Clean):

1. CFO turns durably positive (two consecutive years of positive CFO).
2. Non-GAAP / GAAP gap stays under ¥100M for two years in a row (FY26 + FY27), confirming impairment cycle is over.
3. Inventory days move below 150.
4. Audit committee files a clean first 20-F under the new chair with no qualification.

Position-sizing implication. This is a valuation-haircut and position-sizing forensic profile, not a thesis breaker. The accounting is not the reason to be cautious on YSG — the reason is that a founder-controlled, IPO-cash-funded turnaround in Chinese color cosmetics has a wide outcome distribution and depends on operating execution rather than reported-number quality. A 15–25% margin-of-safety adjustment for governance concentration, acquisition-residue patterns, and FPI disclosure limits is defensible. A full thesis-breaker treatment is not warranted on the evidence in front of us.